ClinicalTrials.gov
public full text
Public Domain
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin \[epoprostenol (Flolan)\], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)#467668
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)#154803
- Guidelines for Drug Therapy of Hypertension: Closing the Loop#125998
- DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study#884179
- Safety of Terbogrel in Patients With Primary Pulmonary Hypertension#846061
Record · ID 861106
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive